Final Judgment Of Non-Infringement Entered In Alnylam V. Pfizer Vaccine Patent Dispute
On July 30, 2025, the U.S. District Court for the District of Delaware entered a Final Judgment in the dispute between Alnylam Pharmaceuticals, Inc. ("Alnylam") and Pfizer, Inc. ("Pfizer")—concluding that Pfizer's COVID-19 vaccine did not infringe any of Alnylam's patents covering nanoparticle technology. Final Judgment in this case follows behind the Court's order on April 28, 2025, denying Alnylam's motion for additional construction of the term "cationic lipid." In this order, the Court noted that the parties had already [...]